BridgeBio announced positive exploratory cardiac data from the 12-month interim analysis of its Phase 3 FORTIFY trial for BBP-418 in LGMD2I/R9. The data showed significant improvements in cardiac injury markers and left ventricular ejection fraction compared to placebo, suggesting BBP-418's potential as a disease-modifying therapy.
BridgeBio presented encouraging exploratory cardiac data from the interim analysis of its Phase 3 FORTIFY trial for BBP-418, a drug targeting Limb-Girdle Muscular Dystrophy Type 2I/R9. The data indicates BBP-418 significantly reduced heart muscle injury markers and stabilized/improved cardiac function compared to placebo. This is a significant positive development as cardiac complications are a major concern in this patient population, and the findings suggest BBP-418 could be a disease-modifying therapy. With the drug under FDA Priority Review and a PDUFA date in November 2026, these positive interim results could bolster its approval prospects and long-term market potential, making BBIO an attractive opportunity for investors looking at long-term growth in the rare disease space.